Public Health Genomics by Zhang, L. et al.
Viral Hepatitis C Gets Personal – The Value of Human Genomics 
to Public Health
L. Zhanga, M. Gwinnb, D.J. Hua
aDivision of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, 
Centers for Disease Control and Prevention, Atlanta, Ga., USA
bMcKing Consulting Corporation, Atlanta, Ga., USA
Abstract
About 180 million people worldwide are chronically infected with hepatitis C virus (HCV), with 
3–4 million newly infected each year. Only 15–25% of acute HCV infections clear spontaneously, 
and the remainder persists as chronic HCV infection. More than 350,000 people die every year 
from hepatitis C-related liver failure and cancer. There is currently no vaccine and the standard-of-
care therapies – peg-interferon alpha (pegIFN) plus ribavirin (RBV) – are expensive and have 
serious side effects. Also, they may be effective in only 40–50% of patients infected with HCV 
genotype 1, the most common HCV genotype in the US. Interleukin 28B (IL28B) genotype was 
recently and convincingly associated with response to pegIFN and RBV therapy. It has emerged as 
a robust pretreatment predictor of sustained virological response (SVR, i.e. virologic clearance) to 
pegIFN and RBV as well as to new triple therapy regimens that include a direct-acting antiviral 
agent with pegIFN and RBV and increase SVR rates as much as 75% in patients infected with 
HCV genotype 1. Testing for IL28B genotype may contribute to clinical decision-making and 
could inform clinical guidelines and public health policies.
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Introduction and Epidemiology
Hepatitis C is an infectious disease primarily affecting the liver caused by the hepatitis C 
virus (HCV). It can range in severity from a mild illness lasting a few weeks to a serious, 
lifelong illness. HCV, a bloodborne pathogen endemic in most parts of the world, infects an 
estimated 180 million people worldwide and causes 3–4 million new infections annually [1]. 
Only 15–25% of acutely infected individuals spontaneously clear HCV, while the remainder 
progress to chronic HCV infection and are, therefore, at risk for cirrhosis and hepatocellular 
carcinoma. Despite the serious illness it can cause, hepatitis C infection is often 
asymptomatic for many years or decades. Hepatitis C has been called a ‘silent epidemic’ 
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because most infected people are unaware that they have a serious and progressive chronic 
disease.
In the US, hepatitis C mortality has increased substantially since the 1990s. Despite small 
declines and leveling of incidence overall in recent years, reports of HCV infection are 
increasing in some areas of the US [2, 3]. Current trends in HCV infection include an 
apparent increase in young, often suburban heroin injection drug users, infections in 
nonhospital healthcare (clinic) settings, and sexual transmission among persons infected 
with human immunodeficiency virus (HIV) [4]. Approximately 25% of persons with HIV 
infection are coinfected with HCV; both infections are associated with injection drug use [5]. 
In the absence of increased screening and treatment, models project an additional 165,900 
deaths from chronic liver disease, 27,200 deaths from hepatocellular carcinoma and USD 
10.7 billion in direct medical expenditures for HCV from 2010 through 2019 [6, 7].
Hepatitis C infection has a great propensity to cause chronic hepatitis, which occurs in 70–
80% of those acutely infected [8]. This often persists and slowly worsens over 10–20 years. 
After acute infection, only 15–25% of persons with normal immune status resolve their 
infection without sequelae. End-stage liver disease can also occur. In 10–20% of chronically 
infected persons, cirrhosis develops slowly over 20–30 years, and hepatocellular carcinoma 
develops in 1–5%. Progression to liver fibrosis, development of cirrhosis and subsequent 
mortality are associated with age at infection, duration of HCV infection, HCV genotype, 
HIV coinfection, alcohol use, and male sex [8].
Hepatitis C Virus
HCV is an enveloped RNA virus within the Flaviviridae family. Its genome consists of a 
positive-stranded RNA molecule (about 9.6 kb) that encodes a large poly-protein precursor 
(about 3,000 amino acids). This precursor protein is cleaved by host and viral proteinases to 
generate at least 10 proteins. These HCV proteins function in viral replication and affect a 
variety of host cellular functions [9].
The genome of HCV is highly mutable. Because HCV is an RNA virus and lacks efficient 
proofreading ability as it replicates, virions infecting humans undergo evolution with time, 
giving rise to the notion that HCV persists as a collection of virus quasispecies. By constant 
mutation in a hypervariable region of the genome coding for the envelope proteins, HCV 
escapes immune surveillance and elimination by the host. As a consequence, most HCV 
infected people develop chronic infection [9].
HCV is highly heterogeneous. Six major genotypes (numbered from 1–6) with several 
distinct subtypes have been identified throughout the world [10]. Genotypes 1a and 1b are 
found worldwide and cause approximately 60% of all cases of infection. This diversity has 
distinct consequences: different genotypes vary in their responsiveness to treatment (see 
below) and their propensity to cause insulin resistance, steatosis, and progression to 
cirrhosis, fibrosis and hepatocellular carcinoma. For example, patients infected with HCV 
genotypes 1 or 4 tend to be more resistant to IFN-based therapies than genotypes 2 or 3 [11]. 
Genetic variation within the core, E2, NS2, P7, NS5A, and NS5B proteins appears to be 
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related to IFN resistance [12] by interfering with IFN pathways and antiproliferative activity 
and contributing to carcinogenesis [13].
Host Interferon Response to HCV Infection
HCV does not kill the cells it infects, but triggers an immune-mediated inflammatory 
response (hepatitis) that either rapidly clears the infection or slowly destroys the liver, 
resulting in the development of cirrhosis and liver cancer. The outcome is largely determined 
by the efficiency of the antiviral immune response. [14]. The strong interferon response to 
HCV infection produces IFN-β secretion from the infected cell. IFN-β binding to the IFN-α/
β receptor signals the Janus kinase/signal transducer and activator of transcription (JAK/
STAT) pathway, which leads to upregulation of several hundred interferon-stimulated genes 
(ISGs). ISG products impart viral regulatory functions that limit HCV replication by 
disrupting viral RNA translation and inhibiting antigenomic strand RNA synthesis. In 
addition to its direct antiviral actions, IFN primes the maturation of immune effector cells 
and potentiates the production of other pro-inflammatory cytokines by resident hepatic cells; 
this process indirectly modulates cell-mediated defenses and adaptive immunity to HCV 
[14]. Current IFN-based therapy exploits the mechanism of induction of ISG expression 
through the IFN-α/β receptor and JAK/STAT pathway to provide antiviral action against 
HCV [12].
Treatment
Chronic HCV infection imposes a major public health burden in part because therapy may 
not be effective and usually has major side effects. HCV elimination is operationally defined 
as causing a sustained virological response (SVR) in which HCV RNA levels cannot be 
detected in blood 6 months after cessation of therapy [15]. A combination therapy with peg-
interferon alpha (peg-IFN) and ribavirin (RBV) is effective in eliminating HCV in only 
about half of patients treated [16]. Success rates are even lower in certain subpopulations, 
such as African Americans, who have an almost 50% reduction in SVR rates with pegIFN 
and RBV compared with Caucasians [17]. Another class of drugs recently approved for use 
by the FDA – direct-acting antiviral agents (DAA), such as telaprevir or boceprevir – cause 
antiviral resistance and virological breakthrough when used as solo therapy. However, triple-
regimen therapy with a DAA plus peg-IFN and RBV greatly enhances SVR rates, up to 75% 
in patients with genotype 1 chronic HCV infection, the most prevalent genotype in the US; 
DAAs are not yet widely available or are too costly in most of the world [15, 18–20].
Because IFN is the backbone of all therapeutic regimens, identifying factors that affect the 
response to IFN therapy is important for clinical decision-making. Several pre- and on-
treatment host and viral variables have been associated with treatment outcome, and some of 
these have become part of decision-making for treatment [21]. Young age, female gender, 
lower weight, normal serum glucose, absence of hepatic steatosis, no or minimal fibrosis on 
liver biopsy, adherence to therapy, lower baseline viral load, and genotypes 2 and 4 are 
positive predictors of SVR [17]. One of the most important predictors of SVR when using a 
combination therapy of pegIFN and RBV is the specific host IL28B genotype [22].
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Host IL28B Genotype, Ethnicity and Response to Interferon Treatment
In late 2009 and early 2010, the association between the IL28B genotype and treatment 
outcome in HCV genotype 1 infection was made by 4 independent groups in genome-wide 
association studies [23–26]. All found that single nucleotide polymorphisms (SNPs) 
rs12979860 and rs8099917 – which tag a haplotype block on chromosome 19 that spans 
IL28B – strongly predict the outcome of pegIFN and RBV treatment in patients infected 
with HCV genotype 1. This finding was consistent among different racial and ethnic 
populations (African American, Asian, Caucasian, and Hispanic). The SNP most associated 
with SVR in Caucasians is rs12979860, whereas in Asians it seems to be rs8099917. 
Individuals carrying the favorable response genotype, containing either rs12979860-CC or 
rs8099917-TT, are at least twice as likely to attain SVR [27–30]. In most populations, except 
African Americans, these 2 SNPs are in strong linkage disequilibrium and similarly 
informative.
The frequency of the favorable response genotype differs across racial/ethnic populations, 
being most frequent in Asians (73%), least frequent in African Americans (13%) and with 
an intermediate frequency in Caucasians (41%) and Hispanics (25%) [23–26, 28, 30]. 
Although the favorable response genotype has a similar effect on treatment response in all 
racial/ethnic groups (Caucasians, odds ratio (OR) = 3.88, (95% CI) = (2.75–5.49); African 
American, OR = 4.63 (2.52–8.50); Asians, OR = 5.66 (3.99–8.02); pooled OR = 4.68 (3.75–
5.83)), its differential distribution contributes very strongly to observed racial disparities in 
overall treatment response [28]. Indeed, African American patients with a favorable 
genotype respond better than Caucasian patients with an unfavorable genotype [23]. 
However, the IL28B genotype does not account for all of the racial differences in response to 
treatment; both IL28B genotype and ethnic background independently predict SVR [31].
Several studies have found that IL28B variants are also associated with likelihood of 
spontaneous clearance of HCV infection. [25, 32–34]. Patients who carry the favorable 
response genotype are twice as likely to clear acute HCV infection without treatment 
(rs12979860-CC, OR = 3.75 (2.42–5.81); rs8099917-TT, OR = 2.67 (1.82–3.91)) [34]. The 
relationship of IL28B genotype with pegIFN and RBV treatment outcome is similar in 
patients infected with only HCV and those coinfected with HCV and HIV [30, 35]. 
However, IL28B genotype has no effect on outcomes of HIV or HBV infection or elite 
control of HIV infection [36–38].
The consistently replicated association of genetic variants of IL28B with treatment outcome 
suggests that its product, interferon lambda 3 (IFN-λ3), has an important role in determining 
viral clearance [39]. The 3 IFN-λs coded by IL28A, IL28B and IL29 were originally 
discovered in 2003 through computational prediction of previously unknown proteins from 
genomic sequence data. The signaling and biological activities of these 3 IFN-λs overlap 
with IFN-α, signaling via the same JAK/STAT pathway leading to induction of IGS 
expression and antiviral proteins. IFN-λ1/2 have shown antiviral activity against HCV in 
vitro, although they are less potent than IFN-α. In a phase 1 study of patients with genotype 
1 chronic HCV infection, pegIFN-λ1 had potent antiviral activity and resulted in a better 
side-effect profile than IFN-α [40]. These outcomes might be due to the fact that the 
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common receptor (IFN-λR) shared by IFN-λs has a more liver-specific distribution than 
IFN-αR. It seems highly likely that the IFN-λ axis will lead to viable therapeutic options in 
the near future.
IL28B variants are the strongest baseline predictor of SVR to pegIFN plus RBV in 
treatment-naïve patients with genotype 1 HCV in multivariable models with other 
independent predictors such as race, baseline viral load, hepatic fibrosis stage, and fasting 
glucose level, across different racial and ethnic populations (African American, Asian, 
Caucasian, and Hispanic) [23, 41, 42]. Patients infected with HCV genotype 1 who have a 
favorable IL28B genotype have a 65% chance of cure with pegIFN and RBV. The favorable 
IL28B response genotype is associated with more rapid viral kinetics and improved the 
treatment outcome independent of ISG expression [41].
IL28B Genotype in the Era of DAAs
The treatment regimen for chronic HCV is currently undergoing a major change with the 
introduction of DAAs. DAAs directly inhibit specific steps in the HCV viral life cycle, for 
example, currently approved boceprevir and telaprevir target NS3 protease. Boceprevir or 
telaprevir in combination with pegIFN and RBV are now considered as optimal therapy for 
chronic HCV genotype 1 infection; both therapies must be given with pegIFN and RBV to 
limit selection of resistant variants and improve antiviral response [15, 22, 43]. Triple 
therapy with boceprevir or telaprevir improves on-treatment kinetics and increases achieved 
SVR rates.
Initial data suggest that IL28B genotype also predicts the response to DAA therapy, although 
its predictive effect might not be as strong as for dual therapy with pegIFN and RBV [44]. 
Patients with favorable IL28B genotype achieve 70% SVR with standard therapy and up to 
90% achieve SVR with triple therapy. The major benefit of DAA appears to be to allow 
short treatment duration [45]. Patients with an unfavorable IL28B genotype have the most to 
gain from the addition of DAA, which doubles the SVR rate in this group (30% with pegIFN 
and RBV only, and 70% with triple therapy); for these patients, the cost-effectiveness and 
risk-benefit will be more favorable [45].
Public Health Implications
Currently, an estimated 3.2 million Americans are living with hepatitis C in the US, most of 
whom (2.1 million) were born from 1945 through 1965 (the ‘baby boomers’). However, up 
to 1.5 million baby boomers have not sought medical treatment because they do not know 
they are infected. To limit HCV-associated morbidity and mortality, the Centers for Disease 
Control and Prevention recently recommended a one-time hepatitis C test for adults born 
during 1945–1964 to identify infected persons and link them to care and treatment [46, 47]. 
This recommendation follows an action plan for prevention, care, and treatment of viral 
hepatitis issued by the US Department of Health and Human Services in 2011 [48]. 
Implementation of this approach could identify 800,000 additional HCV infections and 
prevent more than 120,000 deaths by providing these patients with appropriate treatment 
[46, 47]. IL28B genotype testing could be part of a cost-effective strategy that also improves 
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individual outcomes [49]; a commercial test for IL28B is now available for about USD 300, 
needed to be performed only once in a patient’s life [31].
DAA causes more severe adverse effects than pegIFN and RBV alone [50]; because it is 
costly (USD 1,100 per week for boceprevir, USD 4,100 per week for telaprevir and USD 
954 per week for pegIFN and RBV), access to DAA could be restricted. Universal triple 
therapy with boceprevir (USD 1,100 per week) in all HCV genotype 1 infected patients in 
the US would cost an additional USD 102,600 per quality adjusted life year (QALY) gained 
in the setting of mild fibrosis, compared with the standard dual therapy with pegIFN and 
RBV. Using IL28B guided triple therapy could improve cost-effectiveness; for example, 
treating only those patients with unfavorable IL28B genotypes with a protease inhibitor 
would cost USD 70,100 per QALY in those with mild fibrosis or USD 36,300 per QALY 
with advanced fibrosis in addition to therapy with pegIFN and RBV therapy alone [49]. 
IL28B genotype identifies patients who are likely to attain SVR with a shorter, lower-cost 
regimen (pegIFN and RBV alone); therefore, genetic testing could be helpful in maximizing 
the cost-effectiveness of triple therapy. For example, offering patients with favorable IL28B 
genotypes first-line treatment with pegIFN and RBV, followed by DAA for those who 
relapse, could be more cost-effective than treating all patients initially with regimens 
including DAA [45, 49].
As there is substantial overlap between persons infected with HCV and HIV, coinfected 
individuals represent an important subgroup with chronic HCV infection being one of the 
leading causes of morbidity and mortality among persons with HIV infection [51]. Despite 
the introduction of promising therapies and the ability to assess therapy response through 
IL28B testing, treatment up-take for HCV is unacceptably low, especially among substance 
abusers. Increasing the awareness of these diagnostic and treatment advances among health 
care providers may help to improve treatment uptake among all individuals with chronic 
HCV infection [51].
Conclusion
IL28B variation is strongly associated with response to pegIFN plus RBV therapy in patients 
chronically infected with HCV genotype 1. This discovery has been consistently replicated 
in many populations. IL28B genotype is a strong predictor of treatment outcome at the 
individual level. Even with the introduction of a new class of highly effective DAAs, the 
IL28B genotype continues to serve as a useful predictor of treatment outcome and could 
help to establish treatment expectations and guide decisions for retreatment of prior 
nonresponders as long as IFN continues to be the backbone for antiviral therapy. Testing for 
IL28B variants predictive of therapeutic success should contribute substantially to clinical 
decision-making and formulation of public health policies. The goal of personalized 
healthcare may be one step closer for patients with HCV infection.
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